文献速递浆细胞疾病

MAF作为先锋转录因子启动并维持骨髓瘤发生

MAF functions as a pioneer transcription factor that initiates and sustains myelomagenesis.
PubMed 文献 · Blood Adv · 2023-01-01

研究探讨致癌性MAF作为浆细胞肿瘤多发性骨髓瘤的起始驱动因素对染色质的影响。发现异位表达的MAF激活健康B细胞和浆细胞中原本无活性的增强子和超级增强子,并与浆细胞定义转录因子IRF4协同,赋予骨髓瘤浆细胞迁移和增殖的转录潜能;强制异位MAF表达证实其能将转录惰性染色质转化为具有超级增强子特征的活性染色质,激活MAF特异性致癌转录组并获得CCR1依赖性细胞迁移等癌症相关表型。尽管具有先锋功能,骨髓瘤细胞仍保持MAF依赖性,验证致癌性MAF作为治疗靶点可规避后续遗传多样化导致的疾病复发和耐药挑战。

要点

  • 致癌性MAF作为先锋转录因子激活原本无活性的增强子和超级增强子。
  • MAF与浆细胞定义转录因子IRF4协同激活MAF特异性致癌转录组。
  • 骨髓瘤细胞保持MAF依赖性,支持MAF作为治疗靶点。

核心结论

  • 致癌性MAF作为先锋转录因子既能启动也能维持致癌转录组和癌症表型。
  • 尽管具有先锋功能,骨髓瘤细胞仍保持MAF依赖性,验证致癌性MAF作为治疗靶点可规避后续遗传多样化驱动的疾病复发和耐药挑战。

研究设计与样本

  • 研究致癌性MAF作为癌症起始驱动因素在多发性骨髓瘤中对染色质的影响。
  • 通过强制异位MAF表达验证其将转录惰性染色质转化为活性染色质的能力。

主要发现

  • 异位表达的MAF赋予骨髓瘤浆细胞迁移和增殖的转录潜能。
  • 该潜能由健康B细胞和浆细胞中原本无活性的增强子和超级增强子的激活以及MAF与浆细胞定义转录因子IRF4的协同调节。
  • 强制异位MAF表达证实致癌性MAF能将转录惰性染色质转化为具有超级增强子特征的活性染色质,激活MAF特异性致癌转录组并获得CCR1依赖性细胞迁移等癌症相关细胞表型。

关键数值与推荐

  • 异位表达的MAF赋予骨髓瘤浆细胞迁移和增殖的转录潜能。
  • 强制异位MAF表达证实致癌性MAF能将转录惰性染色质转化为具有超级增强子特征的活性染色质。
  • MAF与浆细胞定义转录因子IRF4协同调节增强子和超级增强子的激活。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Deregulated expression of lineage-affiliated transcription factors (TFs) is a major mechanism of oncogenesis. However, how the deregulation of nonlineage affiliated TF affects chromatin to initiate oncogenic transcriptional programs is not well-known. To address this, we studied the chromatin effects imposed by oncogenic MAF as the cancer-initiating driver in the plasma cell cancer multiple myeloma. We found that the ectopically expressed MAF endows myeloma plasma cells with migratory and proliferative transcriptional potential. This potential is regulated by the activation of enhancers and superenhancers, previously inactive in healthy B cells and plasma cells, and the cooperation of MAF with the plasma cell-defining TF IRF4. Forced ectopic MAF expression confirms the de novo ability of oncogenic MAF to convert transcriptionally inert chromatin to active chromatin with the features of superenhancers, leading to the activation of the MAF-specific oncogenic transcriptome and the acquisition of cancer-related cellular phenotypes such as CCR1-dependent cell migration. These findings establish oncogenic MAF as a pioneer transcription factor that can initiate as well as sustain oncogenic transcriptomes and cancer phenotypes. However, despite its pioneer function, myeloma cells remain MAF-dependent, thus validating oncogenic MAF as a therapeutic target that would be able to circumvent the challenges of subsequent genetic diversification driving disease relapse and drug resistance.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Katsarou A, Trasanidis N, Ponnusamy K, et al. MAF functions as a pioneer transcription factor that initiates and sustains myelomagenesis. Blood Adv. 2023. PMID: 37224458. doi:10.1182/bloodadvances.2023009772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。